(Q37583245)

21 August 2017

1 reference

title

Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen (English)

1 reference

21 August 2017

1 reference

venous thromboembolism

1 reference

Ola E Dahl

1

1 reference

21 August 2017

publication date

19 August 2009

1 reference

Clinical and Applied Thrombosis-Hemostasis

21 August 2017

published in

1 reference

21 August 2017

volume

15 Suppl 1

1 reference

21 August 2017

page(s)

17S-24S

1 reference

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344588

Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344588

The John Charnley Award: prevention of readmission for venous thromboembolic disease after total hip arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344588

The Mark Coventry Award: Prevention of readmission for venous thromboembolism after total knee arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344588

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344588

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344588

Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344588

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344588

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344588

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344588

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344588

Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344588

21 January 2018

Identifiers

DOI

10.1177/1076029609344588

1 reference

21 August 2017

1 reference